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The vascular endothelin system is not overactive in normoten- contribute to basal vascular tone and blood pressure in
sive hemodialysis patients. healthy humans [2]. The effects of ET are mediated by
Background. The hemodynamic significance of elevated en- at least two different receptors [3]: An ET-A receptordothelin-1 (ET) plasma levels in hemodialysis (HD) patients
on vascular smooth muscle cells causes vasoconstrictionis unknown. Therefore, we studied the role of ET in the regula-
[4], while in contrast, an ET-B receptor on endothelialtion of vascular tone in normotensive HD patients and matched
healthy controls (C). cells is related to the release of nitric oxide, prostaglandin
Methods. The forearm blood flow (FBF) responses to aden- I2, and functional vasodilation [5]. ET-B receptors alsoosine, norepinephrine, the ET-A receptor antagonist BQ-123 are expressed on vascular smooth muscle cells (VSMC)(40 nmol/min), the ET-B receptor antagonist BQ-788 (1 and
where they cause vasoconstriction in specific situations50 nmol/min), and ET (5 pmol/min) were measured. Results
[6]. In addition to vasomotion, ET stimulates prolifera-are percent of baseline change  SEM (baseline  100%).
Results. Responses to adenosine and norepinephrine were tion and hypertrophy of VSMC; these effects are medi-
both unchanged in HD. In HD, BQ-123 increased FBF less ated by ET-A and ET-B receptors [5].
than in C (133  9 vs. 178  27%; P  0.02). BQ-788 failed
In chronic renal failure measurable plasma concentra-to change FBF in C but decreased FBF to 83  4% in HD.
tions of ET and big-endothelin-1 are known to be ele-Compared to BQ-123 alone, BQ-123 plus BQ-788 (50 nmol/
min) caused an additional increase of FBF (234  32%, P  vated [7–10], and this led to the theory that ET antago-
0.001) in C, but not in HD (139  14%). This additional in- nists hold great promise for the treatment of renal
crease was absent when BQ-788 was co-infused at 1 nmol/min. diseases, including renal failure [11]. However, the sig-
ET reduced FBF comparably in both groups.
nificance of elevated ET in chronic renal failure is notConclusions. Resistance vessels of HD patients have unre-
clear. For example, Demuth et al determined ET levelsmarkable contractile properties, as shown by responses to
adenosine and norepinephrine. In HD, the basal vascular ET- and studied changes in chronic hemodialysis patients
mediated tone is reduced. The main action of the ET-B recep- [12]. The authors reported a significant correlation be-
tor in C is vasoconstrictive, which also is blunted in HD. The tween plasma ET and cardiovascular remodeling in their
intact response to exogenous ET indicates the normal function
patients. Similar observations were made by Nabokovof ET receptors in HD. Our results could be explained by a
et al, who tested an animal model of arteriosclerosisreduced generation or reduced metabolic clearance rate of ET
in chronic renal insufficiency [13]. On the other hand,in normotensive HD patients. Controversy remains concerning
the role of the ET-B receptor when comparing the present Ottosson-Seeberger et al attempted to correlate mea-
data with previously published literature. surements of ET concentrations in plasma in HD pa-
tients with mean arterial blood pressure, but no correla-
tion was discernible [9]. Hand et al performed functional
Endothelin-1 (ET) is an endogenous peptide with po- studies of ET in patients with chronic pre-dialysis renal
tent properties of a vasoconstrictor. It is primarily se- insufficiency who were also hypertensive. The authors
creted by endothelial cells [1]. ET has been shown to found evidence of a reduced—rather than an increased—
ET-mediated vascular tone [14].
The present studies examined these controversies asKey words: chronic renal failure, hemodialysis, endothelin receptors,
forearm blood flow, resistance vessels, uremia. well as the functional role of ET specifically in chronic
normotensive HD patients, which has not been describedReceived for publication August 30, 2001
previously. Normotensive patients receiving chronic he-and in revised form April 10, 2002
Accepted for publication April 12, 2002 modialysis were selected for study because hypertension
is known to alter the ET system by increasing the ET- 2002 by the International Society of Nephrology
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mediated arterial tone [15]. Forearm blood flow (FBF) in cohort had an unchanged rhEPO treatment for at least
12 weeks prior to the study’s start (Table 1).arterial resistance vessels was measured by strain gauge
Healthy volunteers matched for sex, age and bodyplethysmography, as previously reported by our group
weight were studied as controls. None was taking medi-[16]. Our protocol first sought to establish the response
cation. All were normotensive (blood pressure criteriaof arterial resistance vessels to ET-independent stimuli
the same as for HD patients). General characteristics ofof vasomotion, such as adenosine and norepinephrine.
the participants in the study are in Table 1.The concentrations of ET were measured in peripheral
venous plasma. Patients were infused with the ET-A
Protocol of investigationreceptor antagonist BQ-123 and the ET-B receptor an-
All studies were performed in a quiet temperature-tagonist BQ-788 into the brachial artery. We also infused
controlled room (temperature 22 to 25C) between 9exogenous ET.
a.m. and 4 p.m. with the subjects in a supine position.
All subjects had been asked to refrain from large meals
METHODS and from beverages that contained alcohol or caffeine
during the six hour interval before the study. HD patientsThe study protocol was approved by the ethics com-
were studied during the interdialytic day (12 to 24 hoursmittee of our institution. All participants gave written
after the preceding dialysis). Care was taken that theirinformed consent.
dry weight did not exceed 1.5 kg. A 27 SWG steel cannula
Study subjects (Cooper’s Needle Works, Birmingham, UK) was in-
serted into the brachial artery. The non-dominant armAll participants in the various protocols of this study
was used in the control subjects and the fistula-free armwere taken from an initial population of 15 HD and
in HD patients. Forearm blood flow (FBF) was measured15 control subjects. Renal failure was due to chronic
by strain gauge plethysmography (Gutmann Medizinel-glomerulonephritis (N 6), chronic pyelonephritis (N
ektronik, Eurasburg, Germany) as published previously3), reflux nephropathy (N 2), interstitial nephritis (N
[16]. In control subjects FBF was measured in both arms,2), and autosomal dominant polycystic kidney disease
while in HD patients the measurement of FBF was re-(N 2). Nine HD and eleven control subjects underwent
stricted to the cannulated arm because of the fistula inall parts of the ET-blocker protocols, while six HD pa-
the opposite arm. Individual measurements of FBF weretients and eight control subjects underwent all protocols.
made over three minutes for each determination of FBF.Hemodialysis (HD) patients were recruited from local
For this purpose upper arm cuffs were intermittentlydialysis centers. Patients had been receiving regular (3,
inflated to 40 mm Hg for 10 seconds every 15 seconds4 to 5 h/week) hemodialysis treatment for at least one
to temporarily prevent venous outflow from the forearmyear. Patients were included only when their dry weight
and thus obtain plethysmographic recordings. During pe-had been unchanged for the previous four weeks. Dry
riods of measurement, the blood flow of the hand(s) was
weight was assessed by: (1) ultrasound of the inferior
excluded by a wrist cuff inflated to a suprasystolic pressure.
vena cava, and (2) an absence of edema, dyspnea, intra- After cannulation of the brachial artery, saline was in-
dialytic cramps and drop of blood pressure. HD patients jected first during 30 minutes of equilibration. Thereafter
were normotensive as documented by normal blood at least two baseline determinations of FBF were made.
pressure measurements taken by the dialysis staff before Subsequently, the study drugs were infused over 60 min-
the beginning of the individual dialysis sessions over the utes according to protocols 3 to 6, described in the next
preceding three months (with systolic blood pressure sections. FBF was measured every 10 minutes; arterial
130 mm Hg and diastolic blood pressure85 mm Hg). blood pressure was measured at baseline and at the end
None of the HD patients was taking antihypertensive of each protocol. All agents used were dissolved in 0.9%
medication or non-steroidal anti-inflammatory drugs saline. During the entire study the rate of infusion was
(NSAID). HD patients included in the study did not have constant at 1 mL/min.
any known evidence of arteriosclerosis. In this respect we Protocols 3 to 6, which involved infusions of ET antag-
documented an absence of the following: angina pectoris; onists or ET alone were performed on separate days and
signs of coronary artery disease and chronic heart failure at least one week apart.
by electrocardiogram (EKG) or echocardiography; his-
Protocol 1: Vascular response to adenosinetory of cerebrovascular accident or transient ischemic
attack; and claudication of the legs. HD patients were After measurement of baseline FBF 10 HD patients and
excluded from the study when they had diabetes mellitus, 10 healthy control subjects received an intra-arterial infu-
hypercholesterolemia, liver cirrhosis, or a history of sion of incremental doses of adenosine (75, 150, 300 g/
smoking. Recombinant human erythropoietin (rhEPO) min). Increasing doses were infused subsequently with
a five-minute period of infusion for each dose. Thesetreatment is common in HD patients, and our study
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doses previously have been shown to cause effective local on ice immediately. Plasma was separated within three
vasodilation in the human forearm [17]. to five minutes by centrifugation at 3C and stored at
80C. Plasma levels of immunoreactive ET were mea-
Protocol 2: Vascular response to norepinephrine sured using an ELISA (Biomedica, Vienna, Austria).
Six HD patients and eight healthy control subjects Recovery of ET-1 was 95%. Reported intra-assay and
subsequently received three increasing doses of norepi- interassay coefficients of variation were 4.5% and 6.9%,
nephrine (60, 120, 240 pmol/min). Each dose was infused respectively; the sensitivity of the assay was 0.05 fmol/mL.
over 10 minutes before FBF was measured. Reported cross reactivities of this ET assay were: ET-1
100%, ET-2 100%, ET-3 5%, and big-ET 1%. As
Protocol 3: Vascular response to the ET-A the assay is highly specific for ET-1 and ET-2 and the
receptor blockade latter is not secreted into the blood in humans, the assay
After the determination of baseline FBF values, 9 HD as used in our study may be considered an assay of
patients and 14 control subjects received an intra-arterial plasma ET-1 concentration [20].
infusion of the selective ET-A receptor antagonist BQ-
123 (Clinalfa, La¨ufelfingen, Switzerland), at a dose of 40 Calculations and statistical analyses
nmol/min. The infusion was given over 60 minutes. This All data are reported as mean SEM. For each deter-
dose has been shown in previous studies in the human mination of FBF the mean of the last 10 individual FBF
forearm to fully block the ET-A receptor-mediated ef- measurements for each test period was calculated. Ob-
fects of ET locally, that is in the forearm, without sys- servations are reported as percent of baseline FBF (FBF
temic effect [18]. observed  100/baseline FBF). For statistical analyses
of dose-response relationships, a two-way analysis ofProtocol 4: Vascular response to the ET-B
variance (ANOVA) for repeated measurements wasreceptor blockade
used according to the SPSS software program (SPSS
Ten HD patients and 12 control subjects received an Inc., Chicago, IL, USA). A value of P 0.05 was consid-
intra-arterial infusion of the selective ET-B receptor an-
ered significant. Bonferroni correction for multiple test-
tagonist BQ-788 (Clinalfa) for 60 minutes. The dose was
ing was performed where appropriate. All other parame-50 nmol/min, which has been shown to effectively block
ters were analyzed by the Student paired or unpairedthe ET-B receptor locally in the human forearm [15].
t test as appropriate.The expected concentration of BQ-788 at its receptor
was tenfold higher than the pA2 for BQ-788. The pA2
indicated a twofold shift of the dose-response curve of RESULTS
endothelin-1 to the right at this receptor [19]. As shown in Table 1, HD patients and controls were
comparable in terms of age, sex, gender, height, weightProtocol 5: Vascular response to the combined
and total cholesterol. However, as indicated in each pro-ET-A/ET-B receptor blockade.
tocol, the hematocrit values were significantly lower inTen HD patients and 11 control subjects received si-
HD patients than in control subjects. Mean arterial bloodmultaneous intra-arterial infusion of BQ-123 and BQ-
pressure and heart rate were not different between these788 (dosages as reported in protocols 3 and 4). As a 50-
groups at baseline, nor did they change significantly afterfold lower dose of BQ-788 had been used to block the
the different periods of infusion for control and HDET-B receptor-mediated tone in a prior study by Ver-
subjects. There were no side effects or complicationshaar and coworkers [18], we repeated the combined infu-
during the study. In controls FBF in the non-infused armsion of BQ-123 and BQ-788 in nine healthy control sub-
remained constant throughout each protocol (Table 2),jects, using the lower dose (1 nmol/min BQ-788).
indicating that the locally infused agents did not cause
systemic effects. Baseline FBF values were similar inProtocol 6: Vascular response to exogenous ET-1
both groups (Table 2). In each protocol FBF in the in-Nine HD patients and eight control subjects received
fused arm was comparable between both groups. How-intra-arterial ET (Clinalfa) at a dose of 5 pmol/min for
ever, in HD patients the baseline FBF in the adenosine60 minutes. This dose has been shown previously to cause
protocol was significantly lower than in the protocolsvasoconstriction in healthy subjects and in patients with
where ET antagonists were administered (Table 2).renal insufficiency [14].
Immunoreactive ET plasma levels were significantly
Measurement of plasma levels of ET-1 higher in HD patients than in controls (3.9  0.3 pg/mL,
N  24 vs. 2.7  0.2 pg/mL, N  23; P  0.05). NoPeripheral venous blood was drawn into chilled ethyl-
correlations were found between the ET plasma levelsenediaminetetraacetic acid (EDTA) tubes after patients
had been supine for 30 minutes. The tubes were placed and: (a) the dose of rhEPO; (b) responses to ET, BQ-
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123, BQ-788, and the combined infusion of BQ-123 and
BQ-788; or (c) pulse pressure.
Vascular response to adenosine
Infusion of the vasodilator adenosine caused a dose-
dependent increase in FBF (HD, 339  50%, 530 
81%, 656  110%; control, 267  40%, 426  61%,
584  110% for doses 1 to 3, respectively). These re-
sponses were comparable for HD patients and control
subjects.
Vascular response to norepinephrine
Norepinephrine caused a similar dose-dependent re-
duction of FBF in both groups (HD patients, 85  3%,
71  5%, 52  5%; control, 83  4%, 67  4% and
56  5% for doses 1 to 3, respectively).
Vascular responses to ET-A receptor blockade
Infusion of BQ-123 caused a progressive increase of
FBF in both groups that was maximal at 60 minutes. It
increased FBF in control subjects by 178  27% and in
HD patients by 133 9% (P 0.02; Fig. 1). The increase
in FBF was significantly attenuated in HD patients com-
pared to control subjects.
Vascular response to ET-B receptor blockade
There was no significant difference in the response
to BQ-788 between HD and control subjects (Fig. 2).
However, when the HD patients were analyzed on their
own vasoconstriction to 83.13  4.31 was observed (P 
0.05).
Vascular response to combined ET-A/ET-B
receptor blockade
Simultaneous infusion of BQ-123 and BQ-788 (50
nmol/min) caused a progressive increase in FBF in both
groups (Fig. 3A). BQ-123 plus BQ-788 increased FBF
significantly more in control subjects (234  32%) than
in HD patients (139  14%; P  0.001; Fig. 3A). In
control subjects, but not in HD, the increase in FBF
to the combined infusion of BQ-123 and BQ-788 was
significantly greater than that to BQ-123 alone (P 0.01;
Fig. 3C).
When BQ-788 was co-infused at the lower dose (1 nmol/
min) in nine healthy control subjects (all of whom had
received BQ-123 alone and BQ-123 and BQ-788 at the
higher dose; Fig. 3B), combined infusion of BQ-123 and
BQ-788 increased FBF to the same extent as BQ-123
alone and significantly less than the combined infusion
with BQ-788 at the higher dose (Fig. 3B).
Vascular response to exogenous ET-1
Infusion of ET caused a progressive vasoconstriction
to approximately 50% in both HD and C. In HD the
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Table 2. Response of forearm blood flow to different infusions in control and hemodialysis patients
Control subjects HD patients
Control arm FBF Infused arm FBF Infused arm FBF
Variable mL/100 mL  min mL/100 mL  min mL/100 mL  min
Baseline 2.40.3 2.60.3 2.60.4
BQ-123 2.60.4 4.40.7 3.40.5
Baseline 2.30.4 2.50.4 2.80.2
BQ-788 2.60.4 2.60.4 2.30.1
Baseline 2.40.4 2.10.3 2.20.5
BQ-123/BQ-788 2.40.3 4.60.5 3.10.4
Baseline 2.30.3 2.20.3
BQ-123/BQ-788low 3.20.8 5.11.1
Baseline 2.60.2 2.90.5 3.30.5
Endothelin-1 2.80.3 1.50.2 1.80.4
Baseline norepinephrine 2.00.3 2.20.3 2.40.4
60 pmol/min 1.90.3 1.80.3 2.10.4
120 pmol/min 1.90.2 1.50.2 1.80.3
240 pmol/min 2.00.3 1.30.2 1.30.3
Baseline adenosine 1.80.3 2.00.4 1.60.3
75 g/min 1.80.4 4.81.0 5.31.0
150 g/min 1.70.3 7.21.2 7.61.0
300 g/min 1.80.3 10.31.9 9.31.2
Forearm blood flow (FBF) was in response to intra-arterial infusions of the ET-A receptor antagonist BQ-123 (40 nmol/min), the ET-B receptor antagonist BQ-
788 (50 nmol/min), and the combined ET-A/ET-B receptor blockade by BQ-788 (50 nmol/min) plus BQ-123 (40 nmol/min), endothelin-1, norepinephrine and
adenosine. Note that in control subjects the combined infusion of BQ-123 and BQ-788 was repeated with BQ-788 included at 1 nmol/min. This is indicated by BQ-
123/BQ-788low. Data are given at baseline and at 60 minutes (for adenosine and noreepinephrine at the end of infusion of each dose) for each protocol. For control
subjects the forearm blood flow also is reported for the contralateral arm, indicating potential systemic effects.
Fig. 2. Changes in forearm blood flow in response to intra-arterialFig. 1. Changes in forearm blood flow in response to intra-arterial
infusion of BQ-788 (50 nmol/min) in 10 HD patients () and 12 healthyinfusion of BQ-123 (40 nmol/min) in 9 hemodialysis (HD) patients ()
volunteers (controls; ). Baseline  100%; values are mean  SEM.and 14 healthy volunteers (controls; ). Baseline  100%; values are
mean  SEM. The P value refers to the comparison between the two
groups by two-way ANOVA for repeated measurements.
role in vascular remodeling and in the development of
arteriosclerosis in these patients. Excessive cardiovascu-compared to that of C. This indicates greater sensitivity
lar mortality is well known in HD patients [21]. Weto ET in HD patients. Maximal observed effects at 60
confirmed that plasma ET levels are elevated in normo-minutes, however, were comparable in HD and C (HD
tensive HD patients, as has been reported previouslypatients, 52  6%; control subjects, 55  5%; Fig. 4).
[7–10]. However, the functional role of this ET in vaso-
motion in HD patients is not clear. Therefore, we studied
DISCUSSION the local hemodynamic effects of these elevated plasma
ET levels in normotensive HD patients. NormotensiveThis study was designed to describe the functional
patients were examined in an effort to exclude possiblestate of the ET system in normotensive patients on
confounding factors such as hypertension where in-chronic HD. Carefully matched control subjects were
studied as well. ET has been suggested to play a pivotal creased ET-mediated vascular tone has been shown [15].
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Fig. 4. Changes in forearm blood flow in response to intra-arterial
infusion of endothelin-1 (5 pmol/min) in 9 HD patients () and 8
healthy volunteers (). Baseline  100%; values are mean  SEM.
The P value refers to comparison between the two groups by two-way
ANOVA for repeated measurements. The effect at 60 minutes was
similar in both groups; however, the dose-response curve of HD was
significantly shifted to the left.
For similar reasons, those patients with arteriosclerosis,
diabetes mellitus and hypercholesterolemia and smokers
also were excluded.
First, ET-independent vascular stimuli were tested to
assess any potentially present general changes of vascu-
lar properties in HD patients. Our results obtained by
the infusion of the vasodilator adenosine and the vaso-
constrictor norepinephrine (NE) showed that the general
vasomotive properties were intact and unchanged in HD.
The finding of unchanged NE-mediated vasoconstrictor
tone compared to healthy control subjects was in line
with data obtained by Hand and coworkers [22]. Of
note, this applied to patients treated with rhEPO whereas
patients without rhEPO showed reduced norepineph-
rine-induced constriction. However, our study was not
able to show a correlation between the vasoconstrictor
response to NE and the dose of rhEPO administered,
possibly due to a small number of patients without rhEPO
treatment as well as the fact that our study was not
designed to test this hypothesis. The ET was then in-
fused, and the results showed that (a) at the dose chosen
Fig. 3. (A) Changes in forearm blood flow in response to combined
for our experiments, its dominant effect in HD was vaso-intra-arterial infusion of BQ-123 (40 nmol/min) and BQ-788 (50 nmol/
min) in 10 hemodialysis patients (HD; ) and 11 healthy volunteers constrictive, and (b) there was no difference of effect at
(CTL;). Baseline 100%; values are mean SEM. ***P 0.001 by 60 minutes of infusion between HD and control. Wetwo-way ANOVA for repeated measurements for comparison between
therefore concluded that ET receptors were reactive andHD and CTL. (B) Changes in forearm blood flow in response to com-
bined intra-arterial infusion of BQ-123 (40 nmol/min) and BQ-788 (1 intact in HD. These data do not support any potential
nmol/min) in healthy volunteers (L;) compared to combined infusion down-regulation or post-receptor desensitization of ETof BQ-123 (40 nmol/min) and BQ-788 (50 nmol/min; H; ) and com-
pared to infusion of BQ-123 (40 nmol/min; 123; ) alone. *P  0.05 receptors in HD. Our finding that time-dependent vaso-
for H vs. L and for H vs. 123, by two-way ANOVA for repeated constriction in HD patients was significantly shifted to
measurements. (C ) Maximal changes in forearm blood flow in response
the left, suggesting a higher sensitivity to exogenouslyto combined intra-arterial infusion of BQ-123 (40 nmol/min) and BQ-
788 (50 nmol/min) in 10 HD patients (HD) and 11 healthy volunteers applied ET, is in line with recent results obtained in
(Control) and in response to BQ-123 (40 nmol/min) alone in 9 HD isolated resistance arteries from uremic patients [23].patients and in 14 healthy volunteers. Symbols are: ( ) BQ-123; ( )
BQ-123  BQ-788; **P  0.01 by the Student unpaired t test. Infusions of BQ-123 alone or in combination with BQ-
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788 caused substantial increases in FBF in HD patients, ET-B receptor in healthy volunteers. Their experiments
used selective ET-B receptor blockade and nonspecificwhich showed the existence of a reasonable ET-medi-
ated tone in the forearm resistance vessels of normoten- ET-A and ET-B receptor blockade [18]; however, the
dose of BQ-788 used in their study was 50-fold lowersive HD patients. Compared to control subjects, how-
ever, the increase of FBF in HD was significantly blunted than the dose used in our current study. On the other
hand, Cardillo et al showed an absence of vasoconstric-in both protocols: infusion of BQ-123 alone and infusion
of BQ-123 plus BQ-788. Together these data show a tion in response to ET-B receptor blockade in healthy
volunteers [25]. As in our study, they used BQ-788 at areduced endogenous ET-mediated tone in otherwise un-
remarkable arterial resistance vessels of normotensive dose of 50 nmol/min, which was 50-fold higher than that
used by Verhaar and coworkers. To clarify whether theseHD patients.
Our observations may be explained by (a) a reduced differences were due to a dose effect, we repeated the
combined infusion of BQ-123 with BQ-788 experimentsgeneration of ET together with a reduced clearance of
ET, and (b) inactivation or cleavage of bioactive ET or at 1 nmol/min in healthy control subjects. At this dose
an additional increase in FBF compared to BQ-123 aloneby other mechanisms. We did not perform additional
experiments to further clarify the potential mechanisms was absent. However, we did not observe a blunted in-
crease in FBF compared to the infusion of BQ-123 alone,for the reduced ET-mediated tone in normotensive HD.
However, work done by other groups suggests that the as was shown by Verhaar. There are at least two conceiv-
able possibilities to explain the discrepancies betweeneffect of endogenous ET may be reduced in chronic
renal failure. Hand, Haynes and Webb found a reduced the different doses of BQ-788: BQ-788 as high as 50
nmol/min could cause an additional ET-A receptorvasodilation in response to ET-A receptor antagonism
[14]; but unlike our current study their patients had blockade that results in a further increase in flow. We
did not perform studies to exclude non-specific blockadechronic renal insufficiency not requiring dialysis treat-
ment (mean serum creatinine 400 to 450 mol/L). of ET-A receptors by this high dose of BQ-788. While
Verhaar et al demonstrated that BQ-123 maximallyThe best possible explanation for our observations
appears to be that normotensive HD patients have a blocked ET-A receptors at a dose of 10 nmol/min, our
study used BQ-123 at a dose of 40 nmol/min. This indi-reduced secretion of ET. This is supported by previous
work in vitro that demonstrated a decrease of ET pro- cates that ET-A receptors may have been maximally
blocked by the dose of BQ-123 used in our study andduction by porcine endothelial cells upon exposure to
serum from uremic patients [24]. Furthermore, Hand et therefore an additional non-specific blockade is unlikely.
Moreover, the known specificity of BQ-788 for the ET-Bal suggested that in predialysis chronic renal failure ET-
generation is reduced, too [14]. Taken together, the data receptor is very high and our dose was chosen to achieve
a local concentration in the forearm at least tenfoldfrom the literature and our study argue in favor of a
reduced ET generation in patients with renal failure. higher than the pA2 at the ET-B receptor [19]. Another
explanation would be a dose-dependent effect of BQ-In this view the elevated concentrations of ET-1 in
the peripheral venous plasma of HD patients seem to be 788 on ET-B receptors in different locations [19]. This
could mean that, at the lower dose, BQ-788 blocks onlyperplexing. However, Ottosson-Seeberger et al recently
demonstrated a remarkable decrease of the metabolic endothelial ET-B receptors with subsequent vasocon-
striction due to decreased ET clearance and reducedclearance rate for ET in uremia [9]. They found that the
plasma half-life of exogenous ET was increased in HD nitric oxide production. At higher doses BQ-788 also
could block myocyte ET-B receptors, leading to net vaso-patients; they also proposed that the effective concentra-
tion of ET at its site of action, that is, the subendothelial dilation and increase in local forearm blood flow. How-
ever, our experimental setting does not allow furtherspace, and its measurable concentration in peripheral
venous plasma were not correlated. This is in line with elucidation of this topic. In another study, Strachan et
al recently showed that ET-B receptor agonism by BQ-the absent correlation between ET plasma levels and
the response to ET-A antagonism or combined ET-A 3020 or sarafotoxin s6c causes vasoconstriction in the
forearm circulation in healthy volunteers [26]. Therefore,and ET-B receptor antagonism found in our study. We
therefore suggest that elevated plasma levels of ET in these data also point to a vasoconstrictor effect of ET-B
receptor activation.our HD patients are the result of decreased metabolic
clearance. In control subjects BQ-788 (50 nmol/min) did not
modify local forearm blood flow. This appears to beIn controls, our observations involving the combined
application of BQ-123 plus BQ-788 (50 nmol/min) dem- perplexing. However, as in this setting the vasoconstric-
tive ET-A receptor is unopposed, the vasodilator effectonstrated a role of the ET-B receptor to cause vasocon-
striction. This is at variance with data reported by Ver- of ET-B receptor antagonism may be blunted by dis-
placement of ET to the ET-A receptor. The net effecthaar et al, who showed vasoconstriction for the ET-B
receptor blockade indicating a vasodilatory effect of the might be an unchanged forearm circulation. In HD pa-
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